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PREMATURE OVARIAN FAILURE AND PREMATURE MENOPAUSE IN 
REFUGEE AND IMMIGRANT WOMEN IN THE U.S COMPARED TO 
THAT OF WOMEN BORN IN THE UNITED STATES 
 
VICTORIA ANN DEERING  
ABSTRACT 
 Objective:  Premature ovarian failure is a disease with many far 
reaching and serious consequences.  Little is known about the complete 
etiology of the disease or what women may be at an increased risk for 
developing it.  We sought to evaluate the prevalence of premature ovarian 
failure among women born in the United States and women not born in 
the United States who were patients of Boston Medical Center.  We 
compared the prevalence of POF in these two groups to evaluate any 
relationships that may exist between birthplace and premature ovarian 
failure.  
      Methods:  We collected data from the data warehouse of Boston 
Medical Center.  We used data from women who had an FSH test done 
between the ages of 18 and 40 before June 30, 2013 as the control.  We 
also compiled data of women who had an FSH level over 15mIU/ml as 
well as those who had diagnoses in SDK and Logician.  Birthplaces data 
was also compiled for those women who had an FSH level>15mIU/ml.   
!! vii!
     Results:  Women born outside of the U.S had a slightly higher 
prevalence of POF when compared to women born in the United States.  
Data analysis showed a significant difference among the two groups with 
p<0.0001 for each group.  When birthplace data was compiled, Haiti had 
the highest number of women with FSH>15mIU/ml with Cape Verde and 
the Dominican Republic having the next highest amounts of women.   
    Conclusion:   Our study highlights the possible relationship that exists 
between premature ovarian failure and birthplace.  This was a 
preliminary study to gather data that may be used in future, more 
specific studies to be done on the topic.  These future studies should 
further investigate the reason this relationship exists, other causes that 
may be associated with premature ovarian failure, and further analysis 
of the prevalence of POF in various areas of the world.   
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INTRODUCTION !
      Premature ovarian failure is defined by Arora and Polson (2011) as a 
loss of ovarian function diagnosed when a woman under 40 years old 
presents with four months or greater of amenorrhea and two FSH levels 
that are 30 iu/ml or greater for at least four weeks.  According to Mamas 
and Mamas (2009) this condition affects between 1 and 5 percent of 
women. In North American women the incidence is 10 per 100,000 for 
women aged 15-29, 76 per 100,000 for women aged 30-39 and 881 per 
100,000 for women aged 40-44 (Davis, 1996).  Some common causes of 
POF include genetic abnormalities, enzymatic defects, autoimmune 
diseases, hormone or receptor defects, and various environmental as well 
as physical causes (Rebar, 2005, Schoemaker & Drexhage, 1997).  Most 
cases of POF have no identifiable cause and are thus referred to as 
idiopathic (Mamas and Mamas, 2009).  Patients with premature ovarian 
failure have been shown to have ovarian function return sporadically 
after a diagnosis has been made and there is a 5-10% chance of 
conception after the diagnosis of POF (Kalantaridou, 2012, L.T Shuster et 
al. 2010).   Several authors use the terms premature ovarian failure and 
premature menopause interchangeably but this has recently begun to be 
challenged by some authors including Rahman (2009), Kalantaridou 
(2012), and Nelson et al. (2005).   
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      Menopause is defined by Nelson et al. (2005) as “permanent 
cessation of menses; termination of menstrual life.” Premature 
menopause is therefore defined as permanent cessation of ovarian 
function before the age of 40 (Nelson et al. 2005).  The most common age 
given for natural menopause is 50-52 and studies have shown that the 
later menopause begins, the greater the life expectancy (Gold et al. 2013).  
Premature menopause has some of the same risk factors as premature 
ovarian failure but it is not a reversible condition (Kalantaridou, 2012).  
Premature menopause and premature ovarian failure are used 
interchangeably in the clinic when a woman presents with the symptoms 
and characteristics of premature ovarian failure and thus both terms 
were used for the same condition while gathering data for this study.   
      Women with premature ovarian failure have an increased risk of 
early morbidity, which is due to several factors (S.H Chang et al., 2007).  
These risk factors include osteoporosis, impaired endothelial function, 
and cardiovascular disease (Chang et al., 2007).  Woman diagnosed with 
premature ovarian failure have also been reported to have increased 
anxiety, lower sexual drive, depression, anger, and sensitivity (Shuster et 
al., 2010).  Hormone therapy is the primary treatment offered to patients 
with POF.  This treatment, which replaces some of the estrogen that 
would normally be produced by the ovaries, helps to alleviate the risks to 
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the cardiovascular system and keeps bone density from dropping too low 
(Arora & Polson, 2011).  The diagnosis of premature ovarian failure can 
be very emotional for women as it can mean that their chances of 
conceiving a child are greatly diminished among other concerns they may 
have and thus psychological support is also offered as a part of 
treatment (Singer et al., 2011). 
 
BACKGROUND 
 
      Causes of Premature Ovarian Failure  
      There are several known causes of premature ovarian failure, which 
are listed in Table 1.  According to Béranger et al. there is a known cause 
in only 25% of premature ovarian failure cases, the other 75% are all 
classified as idiopathic (2012). Most of those cases that have a known 
cause are genetic in origin (Rebar 2005).  Recently a few studies have 
been published linking environmental chemicals to premature ovarian 
failure.  These chemicals include diesel exhaust (Ogliari et al., 2013) and 
various chemicals women may be exposed to in their occupations 
(Béranger et al. 2013).  The chemicals associated with premature ovarian 
failure that may be encountered in various occupations will be listed in 
Table 2.   
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      Regardless of the cause, premature ovarian failure occurs by one of 
two main mechanisms.  These mechanisms include depletion of the 
follicular reserves and a malfunction in the maturation of follicles (Arora 
& Pulson 2011).  Turner Syndrome is one of the most common genetic 
abnormalities that cause premature ovarian failure.  It is a 45X 
chromosomal abnormality, which results in early atresia of the follicles 
as well as gonadal dysgenesis (Davis 1996). Fragile X permutations are 
another common chromosomal abnormality that results in premature 
ovarian failure.  It is believed that an increase in FMR-1 transcription 
leads to premature depletion of the follicular reserve (Arora & Pulson 
2011).   
      Iatrogenic premature ovarian failure is usually the result of 
chemotherapy and other cancer related treatment (Arora & Pulson 2011).  
Damage to the ovaries after cancer treatment depends on the age of the 
patient at treatment and the type of treatment received.  Those patients 
at the highest risk of ovarian failure are those treated after puberty, 
those exposed to high doses of alkylating agents, and those exposed to 
high does of radiation to the ovary (Sklar, 2005).   
       Environmental factors may also have a role in causing premature 
ovarian failure.  Ogliari et al found that exposure to acceptable levels of 
diesel exhaust compromised ovarian function of female mice, which 
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diminished their ovarian reserves.  They argue that humans may also be 
affected in the same way and further studies should be done (2013).  
Béranger et al. found that several chemicals that women may be exposed 
to in their occupations can also cause premature ovarian failure (2013).  
The final list compiled by the authors included 20 chemicals that are 
damaging to ovarian reserves (Béranger et al., 2013).  Other 
environmental factors such as cigarette smoking have also been shown 
to increase a woman’s risk of developing premature ovarian failure 
(Chang et al. 2007).  Luborsky et al. found a significant association of 
premature ovarian failure with diabetes, poor health, high BMI, low 
education level, and low income (2002).   
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Table 1. Causes of Premature Ovarian Failure  
Genetic  Fragile X Permutations (Kasteren et 
al 1999), 
Turner Syndrome, FMR1 
permutation, 46XY gonadal 
dysgenesis (Arora & Pulson 2011), 
Mutations in FOXL2, E1F2B, AIRE, 
PMM2, or BMP15 genes (Rebar 
2005) 
Immune Mutations in receptors for FSH and 
LH (Rebar 2005).  
Autoimmune adrenal deficiency, 
APS-1, APS-II, APS-III, thyroid 
autoimmunity (Dragojevic-Dikic et 
al., 2010) 
 
Iatrogenic Radiation, chemotherapy (Sklar 
2005) 
 
 
Physical Viral infections, surgical injury 
(Rebar 2005). 
 
Table 2, Occupational exposure to chemicals implicated in causing 
premature ovarian failure.  This table shows the various environmental 
factors that can be a possible cause of POF.  These are important to note as 
they may be very prevalent in various areas of the world.  Table taken from 
Berenger et al., 2013. 
Chemicals Circumstances of occupational 
exposure  
Lead Exposures are still high among 
craftsmen (manufacture of 
enameled pottery, stained glass, 
crystal), but are generally 
controlled in industry. Tin-lead 
welding in the electronics industry 
generally gives low exposures 
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(unless defective hygiene, nail-
biters, etc.). Possible environmental 
contamination (storage of acid 
foods in enameled dishes, some 
North African cosmetics, shooting 
as a hobby or for sport, 
old lead water-supply pipes 
particularly if attacked by soft 
water, etc.) 
Chromium A trace metal essential to the 
metabolism. Exposure may be high 
in various circumstances: 
metalwork (e.g. electrolytic 
chroming, welding of stainless 
steels with a mass content of more 
than 10% Cr), stabilizing and fixing 
agent for other products (e.g. 
mordant agent in tanneries, wool 
dye fixing agent in the textile 
industry, fixing agent for fungicidal 
and insecticidal metals on wood), 
dyes (chromates, Cr (VI), for dyes 
for plastics, paints, anti-corrosion 
paints, chromium (III) green oxide, 
also present in soaps and 
cosmetics), catalyzer. Also 
present in cements and refractory 
materials. Little leaching of 
chromium to foods stored in 
stainless steel containers. Possible 
exposure through dental 
prostheses, implants, etc. 
Cadmium  80% of Cd is used in manufacture 
of Ni–Cd batteries. Other sources of 
exposure are zinc metallurgy, 
cadmium plating to protect metals 
from corrosion, pigments (yellow–
red) used in particular in plastics, 
ceramics, enamels, glass and 
materials resistant to high 
temperatures, some alloys and 
welding rods with a low melting 
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point. As for other metals, tobacco 
use is a notable source of exposure 
2-Bromopropane Solvent in the electronic industry, 
intermediate agent in the chemical 
and pharmaceutical industries, 
now little used. Unlike 1-
bromopropane, we have found no 
instances of exposure in France 
(request to anti-poison centers). In 
the early 1980s, “NIOSH has 
statistically estimated that about 
1600 workers (including 300 
female) were potentially exposed to 
isopropyl bromide in the USA” 
(HSDB). Occupational exposure to 
isopropyl bromide may occur 
through inhalation and dermal 
contact with this compound at 
workplaces where it is produced or 
used 
2,5-Hexanedione Metabolite of n-hexane, which is 
decreasingly used as it causes 
polyneuritis. May be present in 
glues, petrol, degreasers in the 
automobile industry, solvent in 
paints, vegetable oils 
EGME (2-methoxy ethanol, or 
ethylene glycol methyl ether) 
Solvent in water-based paints, 
resins, inks, dyes, varnishes, 
cosmetics. May be used in the 
electronics industry in Asia, in 
hydraulic fluids, antifreeze in 
aircraft fuel, or as a degreasing 
agent. EGME and its acetate are of 
restricted use since they are now 
classified as reprotoxic agents (ex: 
1-B in EU) 
Hexachlorobenzene Formerly used as a 
fungicide/insecticide. Found as an 
impurity in synthesis of chlorine 
derivatives. Persistent organic 
pollutant. Accumulates in fatty 
tissue 
!=!!
Mancozeb Fungicide still widely used in 
agriculture 
Methoxychlor Former organochlorine insecticide 
(prohibited in Europe in 2002, in 
the USA in 2004) 
Dicofol Organochlorine insecticide formerly 
used in agriculture and building 
industry (miticide, acaricide). Some 
preparations have contained DDT 
residues (or DDT related 
compounds). Recently prohibited in 
Europe (2008), Dicofol use has also 
declined in the USA since 2006, 
and 
is in 2011 the last organochlorine 
pesticide to go through a 
cancellation process to terminate 
all its remaining uses in the U.S. 
(production ceased in 2011, sales 
and distribution will cease in 2013, 
and use will be prohibited since 
2016) 
Carbosulfan Insecticide recently prohibited in 
Europe (2008) 
HBCD Flame retardant, particularly in 
insulating foams in the building 
industry, some plastics, or textiles. 
BMPD Flame retardant (polyester resins 
and polyurethane foams) 
Bisphenol A Production of epoxy or 
polycarbonate resins 
1,3-Butadiene Production of resin and polymers, 
rubber for tyres 
4-Vinylcyclohexene Feedstock in production of organic 
compounds and polymers. Dimer of 
1,3-butadiene. Present in rubber 
vulcanization fumes. “Consumers 
may be exposed to 4-
vinylcyclohexene from volatiles 
from carpets based on monitoring 
data” (HSDB) 
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Isoprene Rubber production (natural rubber 
is an isoprene polymer) 
PAHs Coke, pitch coke, creosote, 
metallurgy, old tars, heated or 
recycled neat cutting oils, products 
of combustion (fires, vehicles). In 
the environment, tobacco smoke 
and cooking fumes (fried food, etc.) 
 
Ethnic Variations in the Diagnosis of Premature Ovarian Failure.   
     Studies have shown some variation in the prevalence of premature 
ovarian failure among different ethnicities (Butts & Seifer, 2010).   The 
percentage of women diagnosed with premature ovarian failure in 
different ethnicities will be listed in table 3.  African American and 
Hispanic women have the highest frequency of premature ovarian failure.  
Chinese and Japanese women have the lowest frequency (Luborsky et al. 
2002).  To our knowledge, there have been no studies that have found an 
explanation for the variation in premature ovarian failure among 
different ethnicities.  Bleil et al. found that African American, Hispanic, 
and Chinese women may have a lower ovarian reserve than Caucasian 
women based on anti-mullerian hormone levels, but further research is 
needed to decide if this has any influence on premature ovarian failure 
(2014).   
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     Table 3. Variations in prevalence of Premature Ovarian Failure by 
ethnicity.   This table shows that African American and Hispanic women have 
the highest prevalence of POF and Japanese women have the lowest prevalence.  
Data taken from Luborsky et al., 2002 
Ethnicity  Prevalence (%) 
African American 1.4 
Hispanic 1.4 
Caucasian 1.0 
Chinese 0.5 
Japanese 0.1 
 
 
Long Term Consequences of Premature Ovarian Failure 
      Women who are diagnosed with premature ovarian failure face many 
long-term consequences.  These can range from physical issues such as 
osteoporosis and cardiovascular diseases to psychological effects such as 
anxiety and depression (Singer et al. 2011).  The younger a woman is 
when premature ovarian failure is diagnosed, the greater the effect these 
consequences can have (Shuster et al. 2010).  It is important that women 
who are diagnosed with premature ovarian failure are made aware of the 
risk factors associated with the disease so that proper precautions can 
be taken.   
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    The physical consequences of premature ovarian failure include:  
osteoporosis, cardiovascular issues, infertility, sexual dysfunction, and 
neurological issues (Shuster et al. 2010). Osteoporosis is a disease 
characterized by low bone density, Shuster et al. found that bone density 
decreases after menopause and the earlier menopause occurs, the 
greater the risk of osteoporosis (2010).  Yorgun et al. have found that loss 
of sex steroids increases a woman’s chance of having a myocardial 
infarction or a stroke (2013). There is also increased chance of ischemic 
heart disease and cardiovascular mortality (Okeke et al., 2013).  
Infertility is a condition that is faced by women diagnosed with 
premature ovarian failure.  Pregnancy may occur in some women with 
POF, but oocyte donation is usually the best way for a child to be 
conceived to affected women (Okeke et al., 2013).  The neurological 
issues that POF patients may face include an increased risk of dementia 
and parkinsonism (Shuster et al., 2010). 
     The psychological issues associated with premature ovarian failure 
include anxiety, depression, and other various emotional issues (Singer 
et al., 2011).  These issues can arise due to the stress of the diagnosis of 
POF.  For many women, a diagnosis of POF may challenge some of the 
preconceived plans they have for the future (Davis, 1996).  The idea that 
a woman my no longer be able to conceive a child naturally is often hard 
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to face, as it is something that many women want for themselves.  
According to Panay and Kulu, the loss of normal reproductive function is 
often very upsetting to women, regardless of whether they have another 
child (2009).  Women also experience stress about other concerns 
associated with POF such as weight gain, body image issues, treatment 
options, management of symptoms, and their overall health (Singer et al. 
2011).   
 
Management of Premature Ovarian Failure 
     According to Panay and Kalu (2009), the management of premature 
ovarian failure should involve professionals from various specialties 
including doctors, counselors that specialize in premature ovarian 
failure, and nutritionists so that every need of diagnosed women can be 
met. Seeing different professionals is important for these women, as 
there are many different facets to this disease.  Counselors provide 
emotional support that a woman may need after she is told having 
children may be harder than she imagined, or when she starts having 
symptoms of menopause well before she had originally expected (Okeke 
et al. 2013).  Reproductive health care specialists can help a women 
understand her options if she wants to have a child (Panay & Kulu, 
2009).   Hormone replacement therapy is the most common treatment for 
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premature ovarian failure (Davis, 1996).  Replacement of estrogen is 
necessary in women with premature ovarian failure; the disease leaves 
them with levels of estrogen that are pathologically low 
(Panay & Kulu, 2009).  The replacement of estrogen reduces a woman’s 
risk of osteoporosis, cardiovascular issues, and some neurologic diseases 
(Panay & Kulu, 2009).  Mamas and Mamas (2009) found that treatment 
using DHEA has been successful in helping women conceive a child 
naturally after diagnosis.  Oocyte donation is also used when women 
with premature ovarian failure are ready to have a child (Okeke et al., 
2013).   
 
 
Justification for this study 
     This study aims to address the prevalence of premature ovarian 
failure in refugee and immigrant populations compared to that of women 
who were born in the United States.  Premature ovarian failure is a 
disease with many consequences, both physical and emotional, there is a 
clear need for studies to be done that will help us to better understand 
this disease.  As was previously discussed, there is some variation in the 
prevalence of premature ovarian failure among different ethnicities.  
There is very little information available that can explain this variation.  
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It is our hope that we may find some connection between premature 
ovarian failure and refugee or immigrant status.  If there is in fact a 
correlation, more research can be done to not only understand why the 
connection exists, but also to discover new ways to prevent the disease.   
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                                        SPECIFIC AIMS 
     The objective of this study is to explore and describe the relationship 
between premature ovarian failure and refugee and immigrant status of 
women in the United States.  The first goal of this thesis is to determine 
the prevalence of premature ovarian failure among the women born in 
the United States and those not born in the United States from the 
population of women treated at Boston Medical Center before June 30, 
2013.  The second goal is to determine if the group of women born 
outside of the United States had a higher prevalence of premature 
ovarian failure than those who were born in the United States.  The last 
goal is to compare the birthplaces of women born outside of the United 
States who have an FSH level over 15mIU/ml to see if there was one area 
that had a higher amount of cases than others.  The results of this thesis 
will be used to formulate future study ideas on the topic of premature 
ovarian failure among women born outside of the United States.   
     It has been suspected by BMC providers that a higher prevalence of 
premature ovarian failure may exist among refugee and immigrant 
populations compared to women born in the United States that are 
patients at Boston Medical center.  We hope this study will shed light on 
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this relationship and open the door for further research to be done on the 
subject.   
MATERIALS AND METHODS  
 
     This is a descriptive study that is designed to describe the prevalence 
of premature ovarian failure among women seen at Boston Medical 
Center before June 30, 2013.  The study population consists of women 
who were born in the United States and those who were not.  The women 
who were not born in the United States are immigrants and refugees 
from other countries.  The data we have used has been collected from the 
Clinical data warehouse database of Boston Medical Center.  This 
database contains the various diagnoses, tests, personal information, 
and other pertinent details of patients at Boston Medical Center. The 
data in this warehouse is all originally from SDK and Logician. SDK is 
the billing and registration software application of Boston Medical 
Center.  Logician, also known as centricity, is Boston Medical Center’s 
outpatient EMR software application.  All of this information can be 
searched electronically and compiled for further analysis.  We searched 
the database for information from women aged 18 to 40 who had an FSH 
test done at the clinic before June 30, 2013.  Women with the diagnosis 
of premature menopause using ICD-9 code 256.31 or menopause status 
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using ICD-9 code V49.81 in SDK or Logician were also included in this 
inquiry.   
    Once data was collected based on the above criteria, we stratified the 
data using several indicators.  These indicators included FSH level and 
the diagnosis recorded in charts. After the initial collection, the data we 
collected were separated into three separate groups.  These groups 
included women with an FSH level over 15, those with a diagnosis in 
SDK and Logician of ICD-9 code 256.31 or V49.81 before age 40, and 
those with either an FSH level greater than 15 or a diagnosis in SDK or 
Logician using the unique ICD-9 codes.  The breakdowns by SDK vs. 
Logician diagnoses were also counted. The separation of the data into 
groups was completed in order to facilitate comparisons of the prevalence 
of premature ovarian failure between the two different groups of women.  
For the purposes of this study, women between 18 and 40 years old who 
had an FSH test done before June 30, 2013 were counted as the control 
group for comparison with the other groups.   In these groups, including 
the control group, the data was broken up into three further groups.  
These groups included: women born in the United States, women not 
born in the United States, and women who had no birthplace listed in 
their charts.  All data collected was then roughly compared using 
percentages before further statistical analysis was completed.  
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      In addition to the other data collected, we recorded the birthplace of 
women seen at the clinic of Boston Medical Center that had an FSH test 
done.  We also recorded the birthplace of the women who had an FSH 
level over 15mIU/ml.  A list was made that included all of these 
birthplaces and the number of patients born in each place was recorded.  
For those women with an FSH level was over 15mIU/ml, birthplace was 
noted and compared to the control group birthplaces. For privacy 
reasons, only countries that had more than 6 women with an FSH test 
over 15mIU/ml were counted with exact numbers.  Any other country 
with 6 or fewer women was simply noted and compiled into a list.  This 
was done to understand if there was a particular part of the world 
outside of the United States that had a higher prevalence of premature 
ovarian failure than the others.  It is important to note that all 
birthplaces recorded are self reported by the patient and thus may be 
misspelled or incorrect. As there is no way for us to correct for this, all 
birthplaces recorded, misspelled or otherwise, will be used in this study. 
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Data Analyses 
     Before statistical analysis was done on the data the number of 
women in each group was compared to the control to find the percentage 
of women tested in both U.S and non-U.S born groups had an FSH level 
over 15mIU/ml.  The same procedure was done to test the groups of 
women who had either an FSH level over 15mIU/ml or a diagnosis in 
SDK or Logician using the respective ICD-9 codes.  Once the initial 
comparison was complete, statistical analysis was preformed.  We 
analyzed the data using SAS (Version 9.2, SAS Institute, Inc., Cary, NC).  
We performed a chi square test in order to check if there was a 
significant difference between proportions of the two groups (U.S born 
Vs. not U.S born).  A p value of p<0.05 was considered to be significant.   
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RESULTS 
  
     There were 8104 unique women with an FSH test done between the 
ages of 18 and 40 before June 30, 2013 listed in the main database that 
had registration information.  Of these 8104 women, 42% were born in 
the United States, 48% were born outside of the United States, and 10% 
had no birthplace listed.  Table 4 shows the exact number of women in 
each sub group.   
 
Table 4. Women with an FSH test preformed before June 30, 2013      
Born in the United States Number  
Yes 3406 
No  3907 
No birthplace listed  791 
   
     There were 600 women in the group who had an FSH level over 15 
mIU/ml.  Of the 600, 594 had birthplaces listed.  Of the 600 when 
compared with the total, 5.3% were in the group born in the United 
States 8.8% were in the group born outside of the United States, and 
9.6% were in the group that had no birthplace listed.  These percentages 
are based on comparison with the original 8104 women using the 
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breakdown into U.S and not U.S born.  Table 5 shows the exact number 
of women in each group.   
    Table 5. Women with FSH>15mIU/ml 
Born in the United States Number 
Yes 180 
No 344 
No birthplace listed 76 
 
     There were 200 unique women with SDK and Logician diagnoses 
using ICD-9 codes 256.31 or V49.81 before the age of 40.  When 
compared to the control group, 2.8% were in the not U.S born group, 
2.0% were in the group born in the U.S, and 2.8% were in the group with 
no birthplace listed.  
 
      Table 6.  SDK + Logician DX(256.31 or V49.81 before age 40) 
Born in the United States  Number  
Yes  67 
No  111 
No birthplace listed  22 
 
There were 639 women who had either an FSH>15mIU/ml or a diagnosis 
in SDK or Logician using ICD-9 codes 256.31 or V49.81.  Of these 
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women, 6.1% were in the group born in the United States, 9.67% were in 
the group not born in the United States, and 6.7% were in the group with 
no birthplace listed.   
 
Table 7. Women with either FSH>15mIU/ml or dx in SDK or Logician 
Born in the United States Number 
Yes  208 
No  378 
No birthplace listed 53 
 
 
     The breakdown of women by diagnosis in SDK versus Logician was 
also done.  No further comparisons will be made with this data but it is 
listed here for completeness.  There were 169 women with a diagnosis in 
SDK before age 40.   There were 97 women with a diagnosis in Logician 
before age 40. 
 
  Table 8.  Breakdown by SDK vs. Logician 
 U.S born Not U.S born  No birthplace 
listed 
SDK 50 99 20 
Logician 57 32 8 
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Data Analysis of those with FSH>15mIU/ml and those with either 
FSH>15mIU/ml or a DX in SDK or Logician 
     The numbers below were used to perform a chi square analysis to test 
the differences between the two groups: U. S born Vs. Not U.S born.   
              FSH>15mIU/ml 
                  % U.S Born(180/3406): 5.3% 
                  % Not U.S Born (344/3907): 8.8% 
             Either FSH>15mIU/ml or DX in SDK or Logician 
                 % U.S Born (208/3406): 6.1% 
                 % Not U.S Born (378/3907): 9.67% 
     There was a significant difference in both comparisons with p<0.0001 
in both groups.  Table 9 contains the breakdown of data from each 
group.  Group 1 contains those women with an FSH value over 
15mIU/ml. The mean age of women born in the United States in this 
group is 34.8, the mean age of those not born in the United States is 
35.86. Group 2 contains those women who had either an FSH value over 
15mIU/ml or a diagnosis of either premature menopause using ICD-9 
code 256.3 or menopause status using ICD-9 code V49.81 in SDK or 
Logician. The mean age of those women born in the United States in this 
group is 34.27, the mean age of those not born in the United States is 
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35.74.  The numbers of women in each group that are not born in the 
United States were used as n in the table and chi square analysis.   
      
Table 9. Comparison of differences in POF prevalence between women 
born in the United States and those that were born outside of the United 
States.   
 P value  Percent of 
group 
Born in 
the US 
Total in 
group 
Women 
excluded 
from group 
criteria 
who had 
an FSH 
test done 
Group 1 
(FSH>15mI
U.ml) 
n=344 
<0.0001 4.70 180 524 6789 
Group 2    
(FSH>15mI
U/ml or dx 
in SDK or 
Logician) 
n=378 
<0.0001 5.17 208 586 6727 
      
Total 
sample 
size in 
each group 
    7313 
 
 Table 10.  Women with no birthplace listed who were not included in the 
chi square analysis  
Group 1 76 
Group 2  53 
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Control  791 
 
Birthplace Data 
  Birthplace data was collected from the women who had an FSH test 
done between the ages of 18 and 40 before June 30, 2013.  The 
birthplaces of women with an FSH test done who were not born in the 
United States are listed in the pages below Table 11.  The countries that 
were the birthplace of more than 15 women are listed with the exact 
number in Table 11. 
  Table 11. Areas outside of the United States with more than 15 women 
who had an FSH test done 
Birthplace Number of Women 
Antigua 17 
Bangladesh 29 
Brazil 77 
Cameroon 18 
Cape Verde 338 
D.R 244 
El Salvador 56 
Eritrea 18 
Ethiopia 76 
Guatemala >57 
Guyana 18 
Guinea  24 
Honduras 50 
Haiti 874 
Jamaica 145 
Lebanon 16 
Liberia 21 
Morocco 53 
Montserrat 41 
Nigeria 129 
Puerto Rico 245 
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Pakistan 20 
Philippines 24 
Portugal 19 
St. Thomas 16 
San Domingo 29 
Sierra Leone 37 
Somalia 56 
Trinidad 44 
Uganda 17 
Venezuela 20 
Vietnam 37 
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List of Birthplaces outside of the United States of women with an FSH test done 
 
Abana, Cuba Eitrea  Northern Ireland AR Georgia Russia 
Albania Ekitrai Norway Arab Germany 
Abudabi, UAE El Salvador Nottingham Arabia Gernada 
Accra, ghana Elaine ar Nova Scotia ARECIBO PR Ghana 
Acores, Portugal England Novacia Argentina Glascow, Scotland 
Addis Ababa, ethopia  Seoul Korea Novi sad Argaria Goiania Brazil 
Africa  Ecuador Obausi Ghana Aritrea Gonaives Haiti  
Afghanistan Eretreal, Africa Odessa Ukraine Armania Granada 
Ghana Erita, Asamara Oman Aruba Greece 
Sierraleone Eritrea Ontario Asmara, Eritrea Granada 
Somalia ERU Oran Algreria Asamara, ethopia Guadalupe 
Angola Estonia  Ordu Ascot, England Guatamala 
Bongo Europe Osaka Aserbajgan Guam 
Camaroon Fajardo, PR Ottawa Asia Guyana 
Nigeria  Filipine Owerri  Athens, Greece Guinea Biffau 
Agadir Finland Oxford England Antigua Gujarat 
Agana, Guam Fogo cape verde Puerto Rico Atina, italy Gulipmala 
Ahiti France P.R China Augburg, germany Gunhaes 
El Salvador Frankfurt Germany Pacific Islands Aukland, NZ Guyama 
Alamagordo NW Mexico Freetown  Pakistan Australia Honduras 
Alexandria, Egypt Fuggia Italy Palestine Austria Ha Nai 
Algeria Fuzhou China Palermo AZ Haifa 
Aman Gabon Palma de mallorca Azores  Haiti 
amgola Gaeta Italy Panama Badgab, iraq Halifax 
aneho Gahna Paraguay Badhdad Hamilton Bermuda 
angora Galway Ireland Paria, Cape verde Bafuta, Africa Hamilton Canada 
Anguilla Gambia  Paris Bagandash Pemea Zanzibar 
Ankra Gana Patiala india Guyana PERU 
Antigua Ganda P.A.P Haiti Geneva Switzerland PeshwAR 
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Anturo Gautamala PEI Canada Peixotocardo           Philippines 
Bamberg, Germany Hait                            Republic  Dominica    Baghdad                Suriname 
Bangkok, Thailand Halifax                        Republic of China      Bahamas                Stockholm 
Bani, DR Hamilton Bermuda      Republic of Congo                                    Bahrain 
Banju, Africa Hamilton Canada Republic of Zambia Bainet, Haiti 
Barbabos Honduras Republique du Mali Honduras 
Barbados Havana Reykjavik Ha Nai 
barbaro Holland Riga Haifa 
Barbbados Hong kong Rio Pineda-Toribo 
Barbedos Hungary  Rio Piedras Pingapore 
Barbobos Iceland Rioberde  Plovdiv  
Barbosa Illah Rivera Soto Maria Poland 
Barcelona Inchon Rivera Uruguay Portugal 
Bardados India Rotan Honduras Prague 
Brazil Indian reserve Romania Praia CV 
Bejing Indonesia Rome Prezza Italy 
Beirut Iraq Rwanda Prince ed island 
Belarouse Iran Russia Progresso Guatemala 
Belarus Ireland Ryadh Saudi Arabia Punjab India 
Beleise Isabela PR S. Africa Purma 
Beleze Israel S. America  Pusan  
Belfast Italy S. Korea Qatar 
Belgium Ivory coast S. Vietnam Quamala 
Belise Jamaica Saigon Quantana 
Belize Japan St. Martin Quatamalea 
Bengaldesh Jauco PR St. Thomas  Quawat 
Benin Jeddah St. Vincent Quebec 
Berat Jerusalem Saipan Quwait 
Berlin Jimenez Alberto Salvador Rabat 
Bermuda Jinja Salvakia Romania 
Bern Jling, China Somali Rangoon Burma 
Beruit Johannesburg SA Samara Rawanda 
!%&!!
Berzil Jordan Sambia Razil 
Bhudan Kampala Africa San Domingo Republic of Georgia 
Bhusawal Kanya San Jose Bulgaria 
Bhutan Karachi San Juan Buraundi 
Bein Hoa Kazakhstan San Salvador Burma 
Bissau Kata India  Sao Tome Burundi 
Bissiu Kathmandy Saudi Arabia Busnia 
Bitburg Kawait Sicily C.R 
Blaise Kenema Africa Scotland C. Verde 
Boastwana Kenya Sierra Leone Cabral Maria 
Bogaria Kent England Senegal Cabrera Franceca 
Bogata Khartoum Seoul Caguaas, PR  
Bolgaria Kiev Serbia Cairo 
BOLIVIA Kindia Guinee Shahrood Calcutta 
Bolton Kinshsa, Africa Shakia Calgary, CA 
Bombay Kiruna Sweden  Shanghai Cali, Colombia 
Bosnia Kitchner Canada Sheffield England Cameroon 
Bowtown, Sierra Leone  Kolkata, India  Shinkolobwe Congo Cambodia 
Botswana Kolwezi Zaire, Africa  Shiraz Iran Canaa 
Br Virgin Is Kongo Africa Shrilaka Canada 
Brazil Kora Sialkot, Pakistan Caneroon 
Brava Korca Albania  Sidney Nova Scotia Canton china 
Brighton UK Korea Sinegal Portugal Cape verde 
Britain  Kosko Singapore Cape haitien hti 
British Guyana Kosovo Sri Lanka Caracas 
British Honduras Kozmaqi feriz Sirvia Cardiff uk 
British virgin islands Kuaite Skopje Cardona margarito 
British west indies Kumasi Slovakia Caribbean  
Brussels Kurdish Slovenia Casa Blanca  
Bucharest, Romania Kushtia Smiguel, Azores Cantania italy 
Budapest Kuwait Somalia Cayes Haiti 
Bulawayo, Zimbabwe Kyrgystan Soukahras, Algeria Cayman islands 
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Ceylon Magog Canada Suttles Veronica Ceech republic 
Chandigarh Makapi, Phi Switzerland Central Africa 
Changchun china  Malaysia Sweden Kyzakstan 
Chechnya Malawi, Africa Sydney, Canada La Paz Bolivia 
Checkoslovakia Mali Sydney, AU La Tronche France 
Chengdu                       Malta                                     Sydney, Nova Scotia             Labana 
Chennai  Managua Syria Lebanon 
Chicoutmi Quebec Manati Taiwan Lagos 
Chile Manchester England Thailand Lahore Pakistan 
China Mangalore India Taipei Lancashire England 
Cobo Verde Manila Tamworth, Aut Langley BC 
Columbia Mannheim Tanzania Laos 
Colon Germany Maecella Tappita Lares PR 
Combodia Mardan Tbilisi Georgia Latvia 
Commenwealth  
of Dominica                   Margao Teheran                                          Leeds UK 
Congo Marshal Islands Tel Aviv Lehoee Pakistan 
Cork Ireland Martinique Thaka Leicester UK 
Corydoniol IA Mauritania Tiber Liberia 
Costa Rica Myanmar Tibet Libya 
Couris Rep Mengo Tirana Ligeria 
Croatia Mexico Trinidad Lima 
Cuba Middle east Tobago Limbe  
Culebra PR Milano  Tocoes Lipya 
Curaco Minsk Belarus Togo Lisbon 
Curacoa Mogadishu Tokyo Lithuania 
Curaso Moldova Toronto Loas 
Cypress Moncton Canada Tortola Loiza PR 
Czech republic Montserrat Tripoli Lome 
D.R Mongolia Tunisia London 
Dakar Monrovia Turkey Lucknow India 
Damascus Montserrat Turnhout Lushnje Albania 
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Darka Sengel Africa  Montenegro Tuxapan Morocco 
Delft Montevideo  UAE Macu 
Delhi India Montreal  Uaxaca, Mexico Macedonia 
DR Congo Moscow Uganda South Arabia 
Demaskus Mozambique Yugoslavia Soviet Union 
Dhaka Bangladesh Mp/india UK SP Honduras 
Djibouti Mpundu Ukraine Spain 
Dominic, west indies Multan Umdirman Sparta Greece 
DOR Mumbai Uruguay St. Croix 
Douala Mwense, Zambia US Samoa St. Davids 
Dublin Myanmar US Virgin Is St. James, Jamaica 
Dubai Mysore India USSR St. Jerome 
E. Africa Nabha India Uthaithani St. Johns 
Ecquador Naibo Kenya Uzbekistan St. Kitts 
Edmonton Alberta Nairobi Vancouver Canada St. Lucia 
Egypt Nanjing  Venezuela St. Michael 
Ethiopia  Nepal Vietnam St. Miguel 
Niberia Netherlands Vienna St. Paolo 
Nicaragua Nevis Victoria, Cameroon St. Petersburg 
Nice France New Delhi Victoria BC Canada St. Ann Jamaica 
Nigeria Newfoundland Vilnius St. Elizabeth 
Niguanda New Glasglow W Africa St. John 
Nogales Mexico New Guanda W Germany St. Kitts 
North Iraq New Zealand WI St. Lucia 
Wallingford  West Bank Yaoundé Cameroon St. Michael 
Warangal Western Europe Yemen St. Miguel 
Warsaw Whales UK Zaire St. Paolo 
Watemala Windsor Ontario Zambia St. Petersburg 
Zanzibar Winnipeg Zimbabwe St. Ann Jamaica 
Ceech republic Sudan Zaire St. Elizabeth 
Central Africa Seychelles  St. John
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     Of the 600 women who had an FSH level over 15mIU/ml, 594 had a 
birthplace recorded.  There were 180 women born in the United States 
that had an FSH>15mIU/ml, the rest of the 594 women were born 
outside of the United States.  The birthplaces outside of the United 
States with six or more women associated with them are listed in table 
12 below.  The number of women from each place is also listed in the 
table.  The country with the highest number of women who had an 
FSH>15mIU/ml was Haiti.  Cape Verde had the second highest amount 
and the Dominican Republic the third.  The country with the highest 
percentage of women with FSH>15mIU/ml is Somalia.  Liberia had the 
second highest percentage, and Ethiopia the third.   
Table 12. Number of women with an FSH>15mIU/ml born in areas 
outside of the United States. 
 
Birthplace Number of 
Women with 
FSH>15mIU/ml 
Total 
Number of 
Women 
with FSH 
test done 
% of women in 
area with 
FSH>15mIU/ml 
Liberia  7 21 33.3 
Brazil 8 77 10.4 
Jamaica 9 145 6.2 
Morocco 10 53 18.9 
Nigeria 15 129 11.6 
Puerto Rico 18 245 7.3 
Somalia 21 56 37.5 
Ethiopia 22 76 28.9 
Dominican Republic 28 244 11.5 
Cape Verde 29 338 8.6 
Haiti 75 874 8.6 
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DISCUSSION !
Prevalence of POF in women born in the U.S vs those NOT born in 
the U.S 
     As the results above show, there is a slightly higher prevalence of 
premature ovarian failure in the group of women born outside of the 
United States.  Of the control group, 8.8% of women with an 
FSH>15mIU/ml were born outside of the United States and 9.67% of 
women with an FSH>15mIU/ml or a diagnosis in SDK or Logician were 
also born outside of the United States. This agrees with our original 
hypothesis.  The chi square analysis that was done on the data shows a 
significant difference exists between the two groups of women with a p 
value <0.0001 in both groups, this is a good indication that future 
studies should be conducted to further investigate the matter.   
 
Birthplaces  
     Current literature gives the prevalence of premature ovarian failure 
by various ethnicities, but no study has given the prevalence by specific 
birthplace.  The prevalence by ethnicity is as follows:  African American 
(1.4%), Hispanic (1.4%), Caucasian(1.0%), Chinese(0.5%) and 
Japanese(0.1%) (Luborsky et al., 2002).  In this study, we did not record 
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the ethnicities of the women in both groups.  We have compiled a list of 
prevalence by birthplace as was shown in the results above.   
     Of the 594 women with FSH>15mIU/ml, only 180 were born in the 
United States.  Of the women born outside of the United States, Haiti 
had the highest amount of women with premature ovarian failure. Haiti 
had over two times the amount of women with POF than the areas with 
the second and third highest amounts.  Cape Verde and the Dominican 
Republic had the second and third highest amount of women with 
premature ovarian failure respectively.  When compared to the number of 
women in each respective area that had an FSH test done, Somalia had 
the highest percentage of women with FSH>15mIU/ml.  The percentages 
are of greater use when comparing birthplace data and will be used in 
further studies on the subject.   
Future Investigations into POF 
     This study has provided sufficient evidence that warrants future 
investigations of the topic.  Very few studies exist that compare the 
prevalence of premature ovarian failure between groups of women born 
in the United States and those that are not.  The results of this study 
only scratch the surface of our hypothesis.  We have significant data that 
proves there is in fact a higher prevalence of premature ovarian failure 
among the population of women not born in the United States.  Future 
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studies should be done to attempt to identify the cause of the higher 
prevalence.  The higher prevalence in certain areas may be associated 
with some of the chemicals associated with premature ovarian failure 
studied by Berenger et al. in 2013.  There may also be other causes that 
are not associated with occupation.   These may include: history of 
trauma, genetics, history of chemical exposure, socioeconomic status, 
smoking, and nutrition.  Further studies should also be conducted to 
further stratify the birthplaces of women with premature ovarian failure.  
We have only done a preliminary analysis of this data and a more 
detailed study would be beneficial for future research.  These studies 
should focus on these factors using a multivariate analysis.   
 Limitations of this Study 
     There are a few factors that were not analyzed in this study that may 
influence its results.  There is quite a large percentage of women for 
which we have no country of origin recorded.  Knowing the birthplaces of 
these women would give more accurate results.  The average age of the 
two groups of women is different by about a year and some other factors 
were not controlled for.  There also may be inaccuracies in the data that 
come from using such a large database as well as human error in the 
initial recording of data into this database.  Some physicians may not 
record diagnoses the same way other physicians do so there also may be 
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some discrepancies with diagnostic data.  Any future studies done by our 
group will control for certain factors to get the most accurate results 
possible.   
  Conclusion 
         As was previously discussed, premature ovarian failure is a 
disease that has many serious consequences.  There are some known 
causes of premature ovarian failure but a majority of cases are idiopathic 
(Dragojevic-Dikic et al., 2010).  More research should be done to shed 
light on any possible correlations between premature ovarian failure and 
various factors such as ethnicity, birthplace, occupation, and 
psychological issues.  This study has provided sufficient evidence that 
there may be a relationship between premature ovarian failure and 
birthplace.  Once more is known about possible causes of premature 
ovarian failure, steps can be taken to try to prevent it in women who may 
be at greater risk of its development. 
!"'!!
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